Skip to content
  • Mediacenter
  • Literature Database
  • Investor News
  • Careers
  • Get in Contact
International (English)
Locale
CytoSorbents Europe GmbH
International (English)
Locale
Hotline
  • The Therapy
    • Background
    • Fields of application for the CytoSorb Therapy
    • Ticagrelor and Rivaroxaban
    • Therapeutic aspects
    • COVID-19
    • Global decision support
    • Product safety
    • Testimonials
  • CytoScore
  • The Studies
    • Multicenter Studies
    • Monocenter studies
    • The CytoSorb-Registry
    • Case of the Month Submission
  • The Adsorber
    • Setup of CytoSorb
    • Usage and Application
    • Technical data
    • Q&A
  • Events
    • Event review
  • Support
    • Mediacenter
    • Reimbursement & Coding of CytoSorb Therapy
    • Newsletter Registration
    • Hotline
  • About us
    • Corporation Management
    • CytoSorbents worldwide
    • Scientific partners
    • 10 Years CytoSorb® Therapy
    • Careers
    • Get in Contact

Recording CytoSorbents Lunch Symposium at the EACTS 2022

Hemoadsorption with CytoSorb in various cardiac surgery indications

Role of CytoSorb hemoadsorption therapy in endocarditis patients

CytoSorbents Introduction EACTS 2020

Removal of Ticagrelor during emergency heart surgery – reduction of complications and costs

Mitral valve endocarditis – new chances to improve the outcome

Aortic surgery – modulation of the inflammatory response

Successful treatment of rhabdomyolysis following heart transplantation

Le patient chirurgical d’urgence sous Ticagrelor (Sous-titres français)

The emergency surgical patient under Ticagrelor (Polish Subtitles)

  • 1
  • 2
  • 3
  • Next
CytoSorbents Europe GmbH
Facebook-f Twitter Linkedin Youtube

CytoSorbents Europe GmbH
Müggelseedamm 131
12587 Berlin

support(at)cytosorbents.com

©2023 CYTOSORBENTS EUROPE GMBH | ALL RIGHTS RESERVED

*CytoSorb Therapy is the use of the CytoSorb adsorber in conditions where elevated levels of Cytokines and/or Bilirubin and/or Myoglobin exist. CytoSorb can also be used intraoperatively for the removal of Ticagrelor and/or Rivaroxaban during Cardiopulmonary-Bypass.

  • Privacy Information
  • Data protection
  • Disclaimer
  • Imprint
CytoSorbents Europe GmbH
  • The Therapy
    • Background
    • Fields of application for the CytoSorb Therapy
    • Ticagrelor and Rivaroxaban
    • Therapeutic aspects
    • COVID-19
    • Global decision support
    • Product safety
    • Testimonials
  • CytoScore
  • The Studies
    • Multicenter Studies
    • Monocenter studies
    • The CytoSorb-Registry
    • Case of the Month Submission
  • The Adsorber
    • Setup of CytoSorb
    • Usage and Application
    • Technical data
    • Q&A
  • Events
    • Event review
  • Support
    • Mediacenter
    • Reimbursement & Coding of CytoSorb Therapy
    • Newsletter Registration
    • Hotline
  • About us
    • Corporation Management
    • CytoSorbents worldwide
    • Scientific partners
    • 10 Years CytoSorb® Therapy
    • Careers
    • Get in Contact
APPLY TODAY
JOBS
International (English)
  • Privacy Policy
  • Data protection
  • Disclaimer
  • Imprint